Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients With Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

NCT00451178 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00451178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00451178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin Versus R-CHOP in the First-Line Treatment of Patients With Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
January 31, 2013
Enrollment
101 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma